Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Roche is enrolling patients in a phase 2/3 trial of its prospect. Scholar Rock has identified its targeting of the latent form of myostatin as a differentiator, but its rivals are claiming their ...

As for Alzheimer's disease, the company has done a Phase 2/3 trial. Both trials had topline data readouts over the past months. Annovis reported repeated delays in the announcement of its Phase 3 ...

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular ...

after its ORMD-0801 candidate missed the mark in a phase 3 trial. The announcement marks the disappointing end of a marathon effort by Oramed to develop an oral insulin formulation for type 2 ...

Dr. Thomas Wagner, founder of the biotech company Orbis Health Solutions and cancer researcher, has made it his life's mission to find a way to treat cancer without the dreaded side effects that ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...

Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the ...

About TROPION-Lung10 TROPION-Lung10 is a global, multicenter, open-label, three-arm phase 3 trial where patients will be randomized in a 2:1:2 ratio to evaluate the efficacy and safety of ...